COSM: COSM expands C-Scrub into veterinary market after passing EN 1656/1657 tests

AI Summary

Cosmos Health (NASDAQ: COSM) said it will extend its C‑Scrub Wash 4% into the veterinary/animal health market, launching first in the UK and planning wider international expansion into a market estimated at ~$68.7B in 2025. Independent EN 1656 (bactericidal) and EN 1657 (yeasticidal) lab testing showed required log reductions versus key reference organisms at undiluted (80%) and 50% concentrations with a 10‑minute contact time, supporting commercial use in veterinary settings but stopping short of regulatory approvals.

Positives

Independent EN 1656 & EN 1657 tests met required bactericidal (≥5 log) and yeasticidal (≥4 log) criteria against specified reference organisms
Planned UK launch leverages existing C‑Scrub human brand, in‑house GMP manufacturing (Cana Laboratories) and distribution footprint
Targets the large and fast‑growing global animal health market (~$68.7B in 2025)

Negatives

Tests are independent standard assays, not the same as regulatory marketing authorizations or product registrations
Testing was performed under 'clean' lab conditions with a 10‑minute contact time, which may not reflect real‑world use
No commercial agreements, orders, pricing or timelines for broader launch were disclosed